Sanofi SA (SNY) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Investments ...
Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to enhance shareholder value.
Sanofi Expects Strong Earnings Growth This Year, Plans $5.2 Billion Buyback
The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch a $5.2 billion share buyback.
Sanofi Plans €5 Billion Buyback, Sees Higher Profit Growth
Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots away from consumer health to focus on fast-growing drugs like its RSV shot.Earnings per share,
Sanofi plans share buybacks, signals more deals post Opella sale
Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large stake in its consumer health unit.
Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara Research consensus. Sanofi reported a business operating profit of 2.58 billion euros in the year-earlier period.
Sanofi targets mid to high single-digit sales growth in 2025 with €5B share buyback plan
Q4 2024 Management View Paul Hudson highlighted significant progress in 2024 towards becoming a focused science-driven biopharma company, supported by the sale of a controlling stake in Opella and prioritization of R&D investments.
Pharmaceutical Technology37m
Sanofi reports Q4 2024 increase in net income to $833m
Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...
Positive Report for Sanofi (SNYNF) from DZ BANK AG
Sanofi (SNYNF – Research Report) received a Buy rating and price target from DZ BANK AG analyst Elmar Kraus today. The company’s shares ...
FiercePharma23h
Sanofi's RSV antibody Beyfortus, after smashing blockbuster sales threshold, still has room to grow in US: execs
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
STAT9d
Sanofi is warned by the FDA over ‘significant’ problems at a key manufacturing plant
The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...
Sanofi upgraded to Buy from Hold at DZ Bank
DZ Bank upgraded Sanofi (SNY) to Buy from Hold with a EUR 122 price target Invest with Confidence: Follow TipRanks' Top Wall Street Analysts to ...
FiercePharma9d
Sanofi API plant hit with FDA warning letter detailing quality, consistency flubs
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...
Employee Benefits4h
Sanofi completes £1.4 billion pensions buy-in
French multinational pharmaceutical and healthcare firm Sanofi has completed a £1.4 billion buy-in for its pension scheme.
Sanofi: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...